Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models

Seminars in Hematology

Volumn 38, Issue 1, 2001, Pages 54-70

  Rego, Eduardo M ^a   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CELL PROTEIN; HYBRID PROTEIN; NUCLEOPHOSMIN; PROTEIN NUCLEAR MITOTIC APPARATUS; PROTEIN PROMYELOCYTE LEUKEMIA ZINC FINGER; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; STAT5B PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 17; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DIMERIZATION; DISEASE ASSOCIATION; DRUG EFFICACY; FUSION GENE; LEUKEMOGENESIS; MOLECULAR GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0035142119     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90006-X     Document Type: Article

References (129)

1. Expression pattern of the RARα/PML fusion gene in acute promyelocytic leukemia
2. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia
3. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
4. The POZ domain: A conserved protein-protein interaction motif
5. Plzf regulates limb and axial skeletal patterning
6. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells
7. Proposal for the classification of the acute leukemias
8. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells
9. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML
10. Major nucleolar proteins shuttle between nucleus and cytoplasm
11. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia
12. Combination of ATRA with G-CSF or RARa agonists enhances differentiation induction of fresh APL cells
13. A decade of molecular biology of retinoic acid receptors
14. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells
15. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
16. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia
17. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia
18. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha
19. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha)
20. NuMA is required for the proper completion of mitosis
21. Primary structure of NuMA, an intranuclear protein that defines a novel pathway for segregation of proteins at mitosis
22. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus
23. Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes
24. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor
25. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2
26. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells
27. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance
28. Differentiation therapy for acute promyelocytic leukemia
29. The nuclear matrix protein, numatrin (B23), is associated with growth factor-induced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody
30. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia
31. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia
32. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
33. Acute promyelocytic leukemia: From genetics to treatment
34. Stat5a and Stat5b: Fraternal twins of signal transduction and transcriptional activation
35. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17); Results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies"
36. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia
37. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party
38. Early myeloid cell-specific expression of the human cathepsin G gene in transgenic mice
39. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences
40. Cleavage of the nuclear matrix protein NuMA during apoptosis
41. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
42. The function of PML in p53-dependent apoptosis
43. Two hits for promyelocytic leukemia
44. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL
45. Transcription therapy for cancer effects of histone deacetylase (HDAC) inhibitors on proliferation, apoptosis and differentiation of leukemic cell lines
46. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
47. In vivo analysis of the molecular pathogenesis of Acute Promyelocytic Leukemia in the mouse and its therapeutic implications
48. Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies
49. Complete remission of t(11;17) positive acute promyelocytic leukemia by all-trans retinoic acid and G-CSF
50. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
51. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins
52. Leukemia initiated by PML-RARalpha: The PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable
53. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies
54. Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukaemia
55. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity
56. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma
57. Acute promyelocytic leukemia cases with nonreciprocal PML/RARα or RARα/PML fusion genes
58. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
59. The acute promyelocytic leukaemia-associated PML gene is induced by interferon
60. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice
61. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein
62. RAR alpha1/ RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: A molecular and laboratory-clinical correlative study
63. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17)
64. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
65. Role of the histone deacetylase complex in acute promyelocytic leukaemia
66. PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu
67. Formation of nucleophosmin/ B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein
68. Binding of matrix attachment regions to lamin polymers involves single-stranded regions and the minor groove
69. High postnatal lethality and testis degeneration in retinoic acid receptor α mutant mice
70. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
71. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation
72. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
73. PML, a growth suppressor disrupted in acute promyelocytic leukemia
74. The biologic function of PML and its role in acute promyelocytic leukemia
75. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells
76. Interferon augments PML and PML/RARα expression in normal meyloid and acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of a retinoid resistant promyelocytic cell line
77. Characterization of the PML/RARα chimeric product of the acute promyelocytic leukemia specific t(15;17) translocation
78. Nucleophosmin/B23 is a target of CDK2/Cyclin E in centrosome duplication
79. Overexpression of retinoic acid receptor alpha suppresses myeloid cell differentiation at the promyelocyte stage
80. Knocking in and out genes and trans genes: The use of the engineered mouse to study normal and aberrant hemopoiesis
81. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties
82. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
83. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines
84. PML/RAR homodimers: Distinct DNA binding properties and heteromeric interactions with RXR
85. Development of acute promyelocytic leukemia (APML) in transgenic mice expressing both the PML-RAR and the reciprocal fusion protein, RAR-PML
86. The t(15;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion
87. Retinoic acid (RA) and As203 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
88. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
89. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma')
90. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells
91. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Groupe Français de Cytogénétique Hématologique, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies"
92. PML in rumor suppression
93. Transcriptional regulation of cellular transformation
94. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
95. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis
96. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
97. Occurrence of resistance to retinoic acid in the acute promyelocytic cell line NB4 is associated with altered expression of the PML/RARalpha protein
98. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
99. Everything you have ever wanted to know about Yin Yang 1
100. Retinoids in cancer therapy
101. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
102. PIC-1/ SUMO-l-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
103. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses
104. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia
105. A mutated retinoic acid receptor-α exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line
106. A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage
107. Identification and characterization of a nuclear scaffold protein that binds the matrix attachment region DNA
108. The role of homeobox genes in normal hematopoiesis and hematological malignancies
109. Role of PML in cell growth and the retinoic acid pathway
110. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
111. PML is essential for multiple apoptotic pathways
112. Retinoid resistance
113. Acute promyelocytic Leukemia
114. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
115. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
116. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia
117. A new variant translocation in acute promyelocytic leukaemia: Molecular characterization and clinical correlation
118. Efficient generation of acute promyelocytic leukemia in mice using a PML/ RARalpha cDNA "knocked in" to the murine cathepsin gene G locus requires Cre-mediated excision of a linked selectable marker cassette
119. TEL/ PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
120. The JAK/STAT pathway
121. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1
122. Accelerated degradation of PML-retinoic acid receptor α (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway
123. Translocation of nucleolar phosphoprotein B23 (37 kDa/pI 5.1) induced by selective inhibitors of ribosome synthesis
124. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins
125. The transcriptional role of PML and the nuclear body
126. A role for PML and the nuclear body in genomic stability
127. Role of SUMO-1-modified PML in nuclear body formation
128. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins